Quick Answer
Contineum Therapeutics, Inc. reported Cash and Equivalents of $75.60 million for fiscal year 2025.
Contineum Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $75.60M | +244.5% |
| 2024 | $21.94M | +41.3% |
| 2023 | $15.53M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $42.63M | +4.3% | +105.1% |
| June 30, 2025 | $20.78M | -73.1% | -7.5% |
| March 31, 2025 | $22.47M | +38.2% | +2.4% |
| December 31, 2024 | $21.94M | +41.3% | -46.3% |
| September 30, 2024 | $40.89M | — | -47.1% |
| June 30, 2024 | $77.23M | — | +374.9% |
| March 31, 2024 | $16.26M | — | +4.8% |
| December 31, 2023 | $15.53M | — | — |
- Contineum Therapeutics, Inc. showed an increase of +244.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Contineum Therapeutics, Inc.’s cash and equivalents has grown by 386.9% (from $15.53 million to $75.60 million).
- The most recent figure is from Contineum Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: